SG178562A1 - Polyhydroxylated bile acids for treatment of biliary disorders - Google Patents

Polyhydroxylated bile acids for treatment of biliary disorders Download PDF

Info

Publication number
SG178562A1
SG178562A1 SG2012013132A SG2012013132A SG178562A1 SG 178562 A1 SG178562 A1 SG 178562A1 SG 2012013132 A SG2012013132 A SG 2012013132A SG 2012013132 A SG2012013132 A SG 2012013132A SG 178562 A1 SG178562 A1 SG 178562A1
Authority
SG
Singapore
Prior art keywords
acid
tetrahydroxy
bile
cholan
compound
Prior art date
Application number
SG2012013132A
Other languages
English (en)
Inventor
Victor Ling
Renxue Wang
Jonathan Ahab Sheps
Original Assignee
Victor Ling
Renxue Wang
Jonathan Ahab Sheps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Victor Ling, Renxue Wang, Jonathan Ahab Sheps filed Critical Victor Ling
Publication of SG178562A1 publication Critical patent/SG178562A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG2012013132A 2009-08-25 2010-08-25 Polyhydroxylated bile acids for treatment of biliary disorders SG178562A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23675009P 2009-08-25 2009-08-25
PCT/CA2010/001338 WO2011022838A1 (en) 2009-08-25 2010-08-25 Polyhydroxylated bile acids for treatment of biliary disorders

Publications (1)

Publication Number Publication Date
SG178562A1 true SG178562A1 (en) 2012-03-29

Family

ID=43627124

Family Applications (1)

Application Number Title Priority Date Filing Date
SG2012013132A SG178562A1 (en) 2009-08-25 2010-08-25 Polyhydroxylated bile acids for treatment of biliary disorders

Country Status (7)

Country Link
EP (1) EP2470553B1 (cg-RX-API-DMAC7.html)
JP (1) JP5909774B2 (cg-RX-API-DMAC7.html)
CN (1) CN102712672B (cg-RX-API-DMAC7.html)
AU (1) AU2010286253A1 (cg-RX-API-DMAC7.html)
BR (1) BR112012004284B8 (cg-RX-API-DMAC7.html)
SG (1) SG178562A1 (cg-RX-API-DMAC7.html)
WO (1) WO2011022838A1 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2758060T (pt) * 2011-09-19 2018-01-24 ETH Zürich Moduladores de ror gama para o tratamento de complicações de diabetes ii
JP6217938B2 (ja) 2011-10-28 2017-10-25 ルメナ ファーマシューティカルズ エルエルシー 小児の胆汁うっ滞性肝疾患の処置のための胆汁酸再循環阻害剤
EA038594B1 (ru) 2011-10-28 2021-09-21 Шайр Хьюман Дженетик Терапис, Инк. Ингибиторы рециркуляции желчных кислот для лечения гиперхолемии и холестатического заболевания печени
ES2822375T3 (es) 2012-06-19 2021-04-30 Intercept Pharmaceuticals Inc Preparación de la forma no cristalina del ácido obeticólico
US9982008B2 (en) 2012-06-19 2018-05-29 Intercept Pharmaceuticals, Inc. Preparation and uses of obeticholic acid
WO2014085474A1 (en) * 2012-11-28 2014-06-05 Intercept Pharmaceuticals, Inc. Treatment of pulmonary disease
EP2781217A1 (en) * 2013-03-18 2014-09-24 ETH Zurich ROR gamma modulators
BR112016002268B1 (pt) 2013-08-01 2022-11-01 The Penn State Research Foundation Uso de inibidores do receptor x farnesoide
CN104523703A (zh) * 2014-12-24 2015-04-22 聂飚 一种游离脂肪酸转运蛋白小分子抑制物的应用
US12186329B2 (en) 2018-08-23 2025-01-07 President And Fellows Of Harvard College Compositions and methods related to cholic acid 7-sulfate as a treatment for diabetes
WO2020117945A1 (en) 2018-12-04 2020-06-11 President And Fellows Of Harvard College Synthetic derivatives of cholic acid 7-sulfate and uses thereof
KR102204406B1 (ko) * 2019-01-23 2021-01-18 (주)샤페론 타우로데옥시콜린산 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 염증성 장질환 예방 또는 치료용 조성물
CN109762043B (zh) * 2019-03-06 2020-07-24 华南理工大学 鹅去氧胆酸及其制备方法
CN120757601A (zh) 2019-05-10 2025-10-10 哈佛大学的校长及成员们 肠道细菌胆汁酸代谢的小分子调节剂
CN116925168A (zh) 2019-08-23 2023-10-24 深圳云合医药科技合伙企业(有限合伙) 胆汁酸衍生物及其组合物和应用
CN110548037B (zh) * 2019-09-24 2023-06-02 江西天元药业有限公司 精制熊胆粉及其增强体质治疗和预防肿瘤和癌症的用途
CN113024624B (zh) * 2019-12-25 2024-09-10 上海科胜药物研发有限公司 一种去氧胆酸的合成方法
WO2022233398A1 (en) 2021-05-04 2022-11-10 Kostner Pharma Gmbh COMPOUNDS FOR REDUCING LIPOPROTEIN(a)
CN115337312B (zh) * 2022-08-19 2025-06-03 金熊药业(珠海横琴)有限公司 胆酸复合物及其制备方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS632932A (ja) * 1986-06-23 1988-01-07 Teijin Ltd 経鼻投与用粉末状組成物
CA2338457C (en) * 1998-07-24 2009-11-17 Seo Hong Yoo Preparation of aqueous clear solution dosage forms with bile acids
US7303768B2 (en) * 1998-07-24 2007-12-04 Seo Hong Yoo Preparation of aqueous clear solution dosage forms with bile acids
WO2006116815A1 (en) * 2005-05-02 2006-11-09 Vanadis Bioscience Ltd Composition for the control of cholesterol levels
WO2006116814A1 (en) * 2005-05-02 2006-11-09 Vanadis Bioscience Ltd Composition and uses thereof
CA2716922C (en) * 2008-02-26 2016-06-28 British Columbia Cancer Agency Branch Polyhydroxylated bile acids for treatment of biliary disorders

Also Published As

Publication number Publication date
BR112012004284A2 (pt) 2017-06-13
BR112012004284B8 (pt) 2021-05-25
CN102712672A (zh) 2012-10-03
WO2011022838A8 (en) 2011-06-16
WO2011022838A1 (en) 2011-03-03
CN102712672B (zh) 2016-09-14
AU2010286253A1 (en) 2012-04-19
EP2470553A4 (en) 2013-02-20
JP5909774B2 (ja) 2016-04-27
BR112012004284B1 (pt) 2021-01-05
EP2470553C0 (en) 2024-06-19
EP2470553A1 (en) 2012-07-04
JP2013502442A (ja) 2013-01-24
EP2470553B1 (en) 2024-06-19

Similar Documents

Publication Publication Date Title
US20200078374A1 (en) Polyhydroxylated bile acids for treatment of biliary disorders
EP2470553B1 (en) Polyhydroxylated bile acids for treatment of biliary disorders
CA2716922C (en) Polyhydroxylated bile acids for treatment of biliary disorders
Evangelakos et al. Role of bile acids in inflammatory liver diseases
Setchell et al. Genetic defects in bile acid conjugation cause fat-soluble vitamin deficiency
Csanaky et al. Organic anion–transporting polypeptide 1b2 (Oatp1b2) is important for the hepatic uptake of unconjugated bile acids: Studies in Oatp1b2‐null mice
Debray et al. Defects in gallbladder emptying and bile acid homeostasis in mice with cystic fibrosis transmembrane conductance regulator deficiencies
Wang et al. Fluorous‐tagged peptide nanoparticles ameliorate acute lung injury via lysosomal stabilization and inflammation inhibition in pulmonary macrophages
Yang et al. Didymin alleviates metabolic dysfunction-associated fatty liver disease (MAFLD) via the stimulation of Sirt1-mediated lipophagy and mitochondrial biogenesis
Wang et al. Hydrophilic bile acids prevent liver damage caused by lack of biliary phospholipid in Mdr2−/− mice [S]
Santini et al. Copper-catalyzed dicarbonyl stress in NAFLD mice: protective effects of Oleuropein treatment on liver damage
Zou et al. A minimalist multifunctional nano-prodrug for drug resistance reverse and integration with PD-L1 mAb for enhanced immunotherapy of hepatocellular carcinoma
WO2006107936A1 (en) The use of ezetimibe in the prevention and treatment of cholesterol gallstones
CN103536921B (zh) 胆固醇代谢物在抑制肝癌生长中的应用
HK1176622A (en) Polyhydroxylated bile acids for treatment of biliary disorders
US20220227804A1 (en) Combination of a polyhydroxylated bile acid and a farnesoid x receptor agonist
HK1176622B (en) Polyhydroxylated bile acids for treatment of biliary disorders
Li et al. Celastrol Triggers CAV-1-Mediated Mitochondrion Cholesterol Metabolism and Mitophagy to Suppress Liver Cancer
Martinefski et al. Cholestasis: The Close Relationship between Bile Acids and Coenzyme Q10
Pan et al. Implications of Bile Acids Activated Receptors in non-infectious diarrhea
Truong Roles for Bile Transporters in the Pathogenesis and Treatment of Liver and Intestinal Diseases
Martinefski et al. Relationship between Bile Acids and Coenzyme Q10
Wen et al. Oral antibiotics promote triple-negative breast cancer progression by inducing gut microbiota dysbiosis and taurocholic acid accumulation
Golonka Sex, Aging, and Gut Microbiota on Bile Acid Metabolism in Liver Cancer
Verkade et al. Articles in PresS. Am J Physiol Gastrointest Liver Physiol (November 8, 2012). doi: 10.1152/ajpgi. 00322.2012